Pricing Log in Create free account
Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

45.66 1.12 +2.51%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alkermes plc (ALKS) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Alkermes plc (ALKS) trades at a EV/Sales of 4.8×. Over the past ten years it has ranged from 1.4× (March 2020) to 18.6× (December 2015); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.8× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.4× (12.06%)
FY2024 2.8× 7.27%
FY2023 2.6× (21.24%)
FY2022 3.3× 18.06%
FY2021 2.8× 10.89%
FY2020 2.5× 7.11%
FY2019 2.3× (36.36%)
FY2018 3.7× (57.29%)
FY2017 8.6× (17.06%)
FY2016 10.3× (44.37%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 4.3× (25.25%)
Jun 2026 5.8× 30.79%
Mar 2026 4.4× 81.54%
Dec 2025 2.4× (10.71%)
43 more quarters

Against its own ten years

Low 1.4× High 18.6×
Ten-year median 3.4×
Current reading's percentile 70

EV/Sales against peers

Company EV/Sales
HIMS Hims & Hers Health, Inc. compare 2.5×
SUPN Indivior Pharmaceuticals Inc. compare 2.7×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.1×
ELAN Elanco Animal Health Incorporated compare 3.2×
RDY Dr. Reddy's Laboratories Ltd compare 3.7×
LNTH Lantheus Holdings, Inc. compare 4.1×
ALKS Alkermes plc 4.8×
KNSA Kiniksa Pharmaceuticals International, plc compare 7.2×
LQDA Liquidia Corporation compare 8.6×
Drug Manufacturers Specialty & Generic industry median 2.8×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ALKS